



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Saturday, November 21, 2009

Genetronics Biomedical

[View the current Genetronics Biomedical Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/4424-Genetronics+Biomedical.html)
(<http://www.bioportfolio.com/bi corporate/4424-Genetronics+Biomedical.html>)

Contact Details:

11199 Sorrento Valley Road
San Diego
CA
92121-1334
United States of America

Tel: (858) 597-6006
Fax: (858) 597-0119
Email: ir@genetronics.com

Genetronics' most advanced effort involves treating those with head and neck cancer, a particularly devastating cancer that can severely limit the ability of these patients to see, taste, hear, talk, breathe, or swallow. Genetronics received approval from the U.S. Food and Drug Administration and initiated Phase II multi-center clinical trials at nine sites in the U.S. The trials test the effectiveness of Genetronics' proprietary drug delivery system as a treatment for cancer of the head and neck in patients with resistant or recurrent cancers who have failed conventional therapy. The Company also has approval from the Health Protection Branch in Canada and has also conducted multi-center clinical trials there.

The clinical trials follow a Phase I/II study at Rush-Presbyterian-St. Luke's Medical Center in Chicago, in which Dr. William Panje observed tumor shrinkage in all ten late stage head and neck cancer patients who were treated with Genetronics' electroporation therapy system. Five of the ten patients experienced complete tumor disappearance and three patients had a partial response of more than 50 percent tumor shrinkage. This treatment consumes less than one hour; compare that to the significant impact of radiation, chemotherapy, or surgery. Most patients have only one treatment.

In France, Genetronics has begun clinical trials at four sites utilizing electroporation therapy with head and neck cancer patients. Additional sites are treating patients with cancer of the liver, pancreas, Kaposi's sarcoma and malignant melanoma.

Press Releases on Genetronics Biomedical:

[Reportlinker Adds Global In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2015](#)

18th November,
2009

Reportlinker

NEW YORK, Nov. 18 /PRNewswire/
-- Reportlinker.com announces that a new market research report is available in its catalogue. *Global In Vitro Diagnostics Investment Opportunities, Analysis and*

[Reportlinker Adds
Biotechnology
Reagents - A Global
Market Perspective](#)

18th November,
2009

Reportlinker

NEW YORK, Nov. 18 /PRNewswire/
-- Reportlinker.com announces that a
new market research report is
available in its catalogue.

*Biotechnology Reagents - A Global
Market Perspective* <http://www>

[Health Robotics
Announces Worldwide
Launch of the "i.v.
Room of the Future"
Concept at Las
Vegas's ASHP](#)

18th November,
2009

BOZEN, Italy, November 18
/PRNewswire/ -- Health Robotics
today announced the worldwide
presentation and launch of its
revolutionary vision for "The i.v.
Room of the Future" at the American
SCHAUMBURG, Ill., Nov. 17

[AVMA Encourages Pet
Owners to Quit
Smoking... for Their
Pets](#)

17th November,
2009

American Veterinary
Medical Association

/PRNewswire-USNewswire/ -- The
American Veterinary Medical
Association (AVMA) is letting
smokers know there is another good
reason to take part in the Great
American Smokeout

[FDA Clears the First
Rapid Test to Detect
Bacteria in Pooled
Platelets](#)

17th November,
2009

Fenwal, Inc.

LAKE ZURICH, Ill., Nov. 17
/PRNewswire/ -- Fenwal, Inc., a
global medical technology company
focused on improving blood
collection, separation, safety and
availability, announced today that the
U.S.

Genetronics Biomedical Patents:



- 7491537- [Nucleic acid formulations for gene delivery and methods of use](#)
- 7173116- [Nucleic acid formulations for gene delivery and methods of use](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

